Highest-materiality recent filing
Sanuwave cuts Q2 2026 revenue guidance to $8.5-9.5M on Ultramist market disruption
Revenue guidance for Q2 2026 reduced to $8.5-$9.5M from prior guidance provided on May 13.
Sanuwave Q1 rev $9.6M (+3.1% YoY); net loss $1.4M; guides Q2 growth 10-15%
Q1 revenue $9.6M, up 3.1% from $9.3M YoY; gross margin 77.3% vs 79.0%.
Sanuwave records Q4 revenue $13.4M (+29.7% YoY); FY rev $44.1M; guides FY26 $51-55M
Q4 2025 revenue record $13.4M (+29.7% YoY); FY 2025 revenue record $44.1M (+35% YoY).
SANUWAVE Health restates prior financials due to sales tax liability of $4.9M-$5.2M
Audit committee determined non-reliance on quarterly and annual reports from March 2024 through September 2025.
Sanuwave Q3 record revenue $11.5M (+22% YoY); guides Q4 $13-14M
Revenue of $11.5M, up 22% YoY and 13% sequentially; highest quarterly revenue in company history.
Sanuwave Health appoints Coyle COO, removes Stegagno; terminates President Walko
Daniel Coyle appointed COO effective Sept 25, 2025; previously VP of Engineering.
Sanuwave signs $28M J.P. Morgan credit facility, repays $27.5M NH Expansion debt
$23M secured term loan (4-yr maturity) + $5M revolver backed by receivables, both at SOFR+350bp.
Sanuwave receives $5M cash from option exercise for patent sale
Licensee exercised option on August 21, 2025, to acquire patents for intravascular shockwave applications.
Sanuwave Q2 revenue $10.2M (+42% YoY), adjusted EBITDA $3.4M; guides Q3 $12-12.7M
Q2 2025 revenue $10.2M, +42% YoY from $7.2M; gross margin 78.3% vs 73.2%.
SANUWAVE Health announces preliminary Q2 2025 revenue of $10.1-10.2M, up 41-42% YoY
Preliminary Q2 2025 revenue $10.1-10.2M, increase 41-42% over Q2 2024.
Sanuwave Q1 revenue $9.34M (+61% YoY); operating income $1.0M; Q2 guidance 40-50% growth
Revenue $9.34M, up 61% from $5.79M in Q1 2024; gross margin 79.0% vs 72.6%; GAAP operating income $1.0M.
SANUWAVE Health reports preliminary Q1 2025 revenue of $9.1M-$9.3M, up 57-61% YoY
Preliminary Q1 2025 revenue $9.1M-$9.3M, highest Q1 in company history; +57-61% vs Q1 2024.
SANUWAVE posts record Q4 revenue $10.3M, FY rev $32.6M; guides 47-53% growth in FY2025
Q4 2024 revenue $10.3M (+47% YoY); full year $32.6M (+60% YoY), both all-time records.
Sanuwave Health receives Nasdaq approval; trading expected to start March 7 under SNWV
Common stock approved for listing on Nasdaq Global Market; trading begins March 7, 2025.
Sanuwave announces preliminary Q4 2024 revenue of $10.1-10.3M, record high, up 44-47% YoY
Q4 2024 revenue expected $10.1-10.3M, highest quarterly revenue in company history; increase of 44-47% YoY.
SANUWAVE Q3 revenue $9.4M (+89% YoY), operating income $2.0M; Q4 guidance 40-50% growth
Revenue record of $9.4M, up 89% vs Q3 2023; beat guidance of 65-75% increase.
Sanuwave completes 1-for-375 reverse split, $10.3M PIPE, and note exchange
Reverse stock split 1-for-375 effective Oct 18; outstanding shares post-restructuring ~8.5M.
SANUWAVE Q2 revenue $7.2M (+53% YoY); guides Q3 growth 65-75%
Q2 revenue $7.2M, up 53% YoY; 72 UltraMist systems sold vs 49 in Q2 2023.
Shareholders approve reverse stock split (1:300-1:500) and 2024 Equity Plan with 516M shares
Proposal 1: Reverse stock split authorized at ratio of 1-for-300 to 1-for-500, with final ratio set by Board.
Sanuwave gets forbearance extension on defaulted notes; $671K consent fee added to principal
Existing defaults under NWPSA continue; lenders forbear remedies until Dec 31, 2024.
Preliminary Q2 2024 revenue $7.0M-$7.2M; up 50%-54% vs Q2 2023 and highest quarterly revenue ever.
Sanuwave terminates merger agreement with SEP Acquisition; pursues alternative capital plans
Terminated merger with SEP Acquisition Corp. on June 25, 2024; notice delivered that day.
Sanuwave Health raises $1.8M: $1.3M convertible notes, $0.5M insider loan; warrants for 65M shares
Issued $1.3M convertible notes (15% interest, $0.04 conversion) and warrants for 65M shares ($0.067/$0.04 exercise).
Sanuwave pays off $6.3M Celularity note for $2.075M, extends SEPA merger deadline to June 30
Paid $2.075 million to settle and extinguish a $6.3 million note and interest owed to Celularity from the 2020 UltraMist acquisition.
Revenue $5.8M (+53% YoY); gross margin 73% (+600bps); UltraMist consumables revenue $4.1M (+64%).
SANUWAVE prelim Q1 revenue $5.7-5.9M, up 51-56% YoY, highest Q1 ever
Preliminary Q1 2024 revenue $5.7M-$5.9M, up 51%-56% vs Q1 2023; highest Q1 in company history.
SANUWAVE fires CFO Toni Rinow without cause, hires Peter Sorensen as replacement
CFO Toni Rinow terminated without cause; receives $335,000 severance equal to one year's base salary.
Q4 2023 revenue record $7.0M (+27% vs Q4 2022 $5.5M); operating income $1.0M vs loss $1.5M.
Licensed intravascular shockwave patent portfolio to Vascular Wave LLC for $2.5M upfront; option to acquire for additional single-digit millions.
SANUWAVE Health shareholders approve merger with SEP Acquisition Corp.
Proposal 1 (merger agreement) approved with 798,379,869 For, 5,221,765 Against, 71,525 Abstain.
In connection with Ms. Gilmore’s termination, Dustin Libby joined the Company as Executive Vice President of Commercial Operations on June 3, 2025.
On May 30, 2025, Nanci Gilmore, the Chief Commercial Officer of Sanuwave Health, Inc. (the “Company”), was terminated without cause, effective as of the same date.
To fill the vacancy resulting from Mr. Stolarski’s resignation, the Board appointed Gregory Bazar to the Board, effective as of May 27, 2025, to serve as a director of the Company until the 2025 annual meeting of stockholders and until his successor is elected and qualified, or until his earlier death, retirement, disqualification, resignation or removal.
On May 26, 2025, A. Michael Stolarski, a member of the Board of Directors (the “Board”) of Sanuwave Health, Inc., a Nevada corporation (the “Company”), notified the Company of his decision to resign from the Board, effective May 27, 2025.
on January 3, 2025, Timothy Hendricks separated from service as Executive Vice President of Sales of Sanuwave Health, Inc. (the “Company”), effective as of the same date.
On January 3, 2025, Timothy Hendricks separated from service as Executive Vice President of Sales of Sanuwave Health, Inc. (the “ Company ”), effective as of the same date.
Mr. Richardson resigned as a director of the Company on November 12, 2024
On April 1, 2024, the Company announced its appointment of Peter Sorensen as its new Chief Financial Officer and designated him the principal financial officer of the Company, effective on the same date.
On March 28, 2024, Sanuwave Health, Inc. (the “Company”) terminated without cause its chief financial officer, Toni Rinow, effective immediately.
Effective July 31, 2023, the Board of Directors of SANUWAVE Health, Inc. (the “Company”) appointed Andrew Walko as the Company’s President.
determined that Ms. Sundstrom no longer satisfies the definition of "officer" set forth in Rule 16a-1(f) promulgated under the Securities Exchange Act of 1934
Mr. Frank will succeed Kevin A. Richardson, II, the former Chief Executive Officer of the Company, who stepped down as Chief Executive Officer on May 23, 2023 to serve as the Company’s Chief Strategy Officer.
Max materiality 0.85 · Median 0.65 · Most common event earnings